270 related articles for article (PubMed ID: 25996601)
1. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
[TBL] [Abstract][Full Text] [Related]
2. EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
Mohammadpour S; Goodarzi HR; Jafarinia M; Porhoseingholi MA; Nazemalhosseini-Mojarad E
J Cell Physiol; 2020 Apr; 235(4):3604-3611. PubMed ID: 31549400
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells.
Tseng-Rogenski SS; Chung H; Wilk MB; Zhang S; Iwaizumi M; Carethers JM
PLoS One; 2012; 7(11):e50616. PubMed ID: 23226332
[TBL] [Abstract][Full Text] [Related]
4. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
5. Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features.
Lee HS; Park KU; Kim DW; Lhn MH; Kim WH; Seo AN; Chang HE; Nam SK; Lee SY; Oh HK; Kang SB
Curr Mol Med; 2016; 16(9):829-839. PubMed ID: 27889996
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias.
Lee SY; Chung H; Devaraj B; Iwaizumi M; Han HS; Hwang DY; Seong MK; Jung BH; Carethers JM
Gastroenterology; 2010 Nov; 139(5):1519-25. PubMed ID: 20708618
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
9. MSI-L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients.
Torshizi Esfahani A; Seyedna SY; Nazemalhosseini Mojarad E; Majd A; Asadzadeh Aghdaei H
J Cell Physiol; 2019 Aug; 234(8):13128-13136. PubMed ID: 30549036
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
[TBL] [Abstract][Full Text] [Related]
12. No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers.
Kondelin J; Martin S; Katainen R; Renkonen-Sinisalo L; Lepistö A; Koskensalo S; Böhm J; Mecklin JP; Cajuso T; Hänninen UA; Välimäki N; Ravantti J; Rajamäki K; Palin K; Aaltonen LA
Genes Chromosomes Cancer; 2021 Jul; 60(7):463-473. PubMed ID: 33527622
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
14. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract][Full Text] [Related]
16. EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression.
Carethers JM; Koi M; Tseng-Rogenski SS
Genes (Basel); 2015 Mar; 6(2):185-205. PubMed ID: 25836926
[TBL] [Abstract][Full Text] [Related]
17. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H; Zaanan A; Sinicrope FA
Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
[TBL] [Abstract][Full Text] [Related]
19. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
Niv Y
Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
